References
- Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003;48:1190–9.
- Ramirez A, Varga J. Pulmonary arterial hypertension in systemic sclerosis. Treat Respir Med 2004;3:339–52.
- Hachulla E, Coghlan JG. A new era in the management of pulmo-nary arterial hypertension related to sderoderma: endothelin re-ceptor antagonism. Ann Rheum Dis 2003;63:1009–14.
- Channick RN, Simommeau G, Sitbon 0, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antago-nist bosentan in patients with pulmonary hypertension: a random-ized placebo-controlled study. Lancet 2001;358: 1119–23.
- Girgis RE, Mathai SC, Krihnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in idiopathic pulmo-nary arterial hypertension and pulmonary arterial hypertension associated with the sderoderma spectrum of diseases. J Heart Lung Transplant 2003;24:1626–31.
- Yamane K, Miyaushi T, Suzuki N, Wheeler-Jones C, Olsen I, Penny R, et aL Significance of plasmaendothelin-1 levels in pa-tients with systemic sclerosis. J Ftheumatol 1994;21:1838–44.
- Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hyper-tension in systemic sclerosis: an analysis of 17 patients. Br J Ftheumatol 1996;35: 989–93.
- Stupi AM, Steen VD, Owes GR, et aL Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515–24.
- Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reac-tions. Clin Pharmacol Ther 2001;69:223–31.
- Gasser S, Kuhn M, Speich R. Severe necrotizing leucocytoclastic vasculitis on a patient taking bosentan. BMJ 2003;329:430.
- Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Ftheumatology 2003;42:191–3.
- Snyder MJ, Jacobs MR, Gran RG, Wilkers DS, Knox KS. Resolu-tion of severe digital ulceration during a course of bosentan therapy. Ann Intern Med 2005;142:802–23.
- Ramos-Casals M, Brito-Zeron P, Nardi N, Claver G, Ftisco G, Parraga FD, et al. Successful treatment of severe Raynaud's phe-nomenon with bosentan in four patients with systemic sclerosis. Ftheumatology 2004;43:1454–6.
- Korn HJ, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis. Prevention by treatment with Bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985–93.